# OnCo record krt-232 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/krt-232/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "krt-232" ;
  schema:name "KRT-232"@en ;
  schema:description "KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53."@en ;
  schema:url <https://onco.cc/drugs/krt-232/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=KRT-232>, <https://www.kartosthera.com> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "small molecule" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:targets <https://onco.cc/targets/mdm2/>, <https://onco.cc/targets/tp53/> ;
  onco:companies <https://onco.cc/companies/kartos-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05797831/>, <https://onco.cc/trials/nct04502394/>, <https://onco.cc/trials/nct03669965/> .